$KLRS Cashflow Statement | Understand Stock

$KLRS

$1.86 +$0.06 (3.33%) Close

$KLRS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operations:
Depreciation and amortization
Amortization and accretion of discounts on short-term investments
Non-cash lease expense
Non-cash gain on lease termination and remeasurement
Impairment costs
Royalty obligation expense - related party
Depreciation expense
Stock-based compensation expense
Capital contributions - in-kind services - related party
Change in fair value of derivative liabilities (including $1,165 and $2,039 for a related party)
Change in fair value of tranche liability (including $331 and $19,064 for a related party)
Non-cash interest expense (including $1,384 and $2,656 for a related party)
Non-cash operating lease expense
Net amortization of premiums and accretion of discounts on marketable securities
Loss on extinguishment and on issuance of convertible promissory notes (including $169 and $34,692 for a related party)

Changes in assets and liabilities:
Interest receivable
Prepaid expense and other current assets
Other non-current assets
Income tax payable
Accounts payable, accrued expenses, other liabilities and amount due to related party
Accounts payable
Accrued expenses and other current liabilities (including $16 and $0 for a related party)
Operating lease liabilities
Net cash used in operating activities
Cash flows from investing activities:
Purchases of short-term marketable securities
Maturities of short-term marketable securities
Purchase of property and equipment
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from issuance of stock under the 2020 Employee Stock Purchase Plan
Proceeds from issuance of common stock in private placement
Proceeds from issuance of pre-funded warrants in private placement
Payment of issuance costs
Proceeds from the issuance of redeemable convertible preferred stock, net of issuance costs
Proceeds from the issuance of convertible promissory notes (including $3,402 and $19,041 from a related party), net of issuance costs
Cash acquired in connection with the Merger
Payment of deferred transaction costs and issuance costs
Proceeds from the exercise of stock options
Net cash provided by financing activities
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
Net increase (decrease) in cash and cash equivalents and restricted cash
Cash and cash equivalents and restricted cash, at beginning of the period
Cash and cash equivalents and restricted cash, at end of the period
Unrealized (loss) gain on available-for-sale securities
Reduction of right-of-use asset due to termination and remeasurement
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents
Restricted cash
Total cash, cash equivalents and restricted cash, at end of the period
Supplemental disclosure of cash flow information:
Income taxes paid, net of refunds
Right-of-use assets obtained in exchange for operating lease liability
Reduction of right-of-use asset due to modification
Reduction of right-of-use asset due to modification and remeasurement
Purchase of property and equipment included in AP and accrued expenses
Merger transaction costs recognized in additional paid-in capital
Recognition of AlloVir common stock outstanding at the closing of the Merger
Issuance of redeemable convertible preferred stock upon conversion of convertible promissory notes
Conversion of redeemable convertible preferred stock into common stock in connection with the Merger
Conversion of convertible promissory notes and accrued interest in connection with the Merger
Deferred transaction and financing issuance costs included in accounts payable and accrued expenses and other current liabilities
Unrealized gain on available-for-sale securities
Capital contributions in-kind services related party
Premium on issuance of convertible promissory notes (including $169 and $15,296 for a related party)
Repurchase of common stock shares for royalty obligation
Vesting Of Restricted Stock Awards

Comments